Zanubrutinib + Obinutuzumab
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Waldenström's Macroglobulinemia
Conditions
Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
Trial Timeline
Apr 26, 2022 → Aug 1, 2028
NCT ID
NCT05326308About Zanubrutinib + Obinutuzumab
Zanubrutinib + Obinutuzumab is a pre-clinical stage product being developed by BeOne Medicines for Waldenström's Macroglobulinemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05326308. Target conditions include Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05326308 | Pre-clinical | Recruiting |
| NCT03332017 | Phase 2 | Completed |
Competing Products
1 competing product in Waldenström's Macroglobulinemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zanubrutinib | BeOne Medicines | Approved | 82 |
Other Products from BeOne Medicines
ZanubrutinibApproved
82
Tislelizumab + Pamiparib + Temozolomide + Sitravatinib + Ociperlimab + BAT1706 + Fruquintinib + BGB-15025 + Zanidatamab + BGB-A445 + Surzebiclimab + Lenvatinib + LBL-007Phase 3
74
Zanidatamab + Tislelizumab + Trastuzumab + Capecitabine + Oxaliplatin + Cisplatin + 5-FluorouracilPhase 3
74
Zanubrutinib + Bendamustine + Rituximab + VenetoclaxPhase 3
74
Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochloride + CarboplatinPhase 3
74